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Reply:
We agree that patients with hepatitis B e antigen (HBeAg)-positive
chronic hepatitis B and normal aminotransferase levels (immune-tol-
erant phase) are at risk for developing hepatocellular carcinoma al-
though it is unclear what the risk is compared with patients with
HBeAg-positive chronic hepatitis B and elevated aminotransferase lev-
els. Therefore, we recommended that these patients be monitored
every 6 months and more frequently when aminotransferase levels
became elevated. In addition, as per our Practice Guideline, physicians
should consider periodic alpha-fetoprotein testing in these individuals.
We also recommended that liver biopsy examination be considered
and antiviral treatment initiated if the patients remained HBeAg pos-
itive with hepatitis B virus–DNA levels greater than 105 copies/mL
after a 3- to 6-month period of elevated aminotransferase levels. We
did not recommend the initiation of antiviral treatment when the
aminotransferase level was persistently normal because of the low rate
of response to currently approved treatment (almost identical to pla-
cebo). Our recommendation was based on the lack of evidence that
current treatment could alter the outcome of these patients and not on
any misguided assumption that these patients would not develop any
adverse sequelae in the future. We agree that clinical trials of new
treatment that is more potent and/or effective in overcoming the lack
of host immune response should include patients with HBeAg-positive
chronic hepatitis B and normal aminotransferase levels. Practice
Guidelines are evidence-based documents. Until data supporting that
treatment can result in virologic response and/or improve clinical out-
come are available, we feel that it would be inappropriate to revise the
Practice Guidelines with regard to treatment of HBeAg-positive pa-
tients with normal aminotransferase levels.
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